Durham-based Biocryst sells licensing rights to Japanese firm in $22M deal
BioCryst Pharmaceuticals has licensed commercialization rights in Japan to Torii Pharmaceutical for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
